Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biocartis Group NV's enterprise value is €154.31 Mil.
Biocartis Group NV's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-41.56 Mil. Therefore, Biocartis Group NV's EV-to-EBITDA for today is -3.71.
The historical rank and industry rank for Biocartis Group NV's EV-to-EBITDA or its related term are showing as below:
LTS:0R72's EV-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 17.13 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Biocartis Group NV (LTS:0R72) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biocartis Group NV's PE Ratio (TTM) for today is calculated as:
Biocartis Group NV's share price for today is €0.298.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.920.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biocartis Group NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R72 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Biocartis Group NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocartis Group NV EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biocartis Group NV's EV-to-EBITDA falls into.
Biocartis Group NV's current Enterprise Value is €154.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-41.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocartis Group NV (LTS:0R72) has a EV-to-EBITDA of -3.71 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biocartis Group NV.
Is Biocartis Group NV's EV-to-EBITDA too high?
Biocartis Group NV's current EV-to-EBITDA is -3.71. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's EV-to-EBITDA compare to TMO and DHR?
Biocartis Group NV's EV-to-EBITDA of -3.71 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EV-to-EBITDA is 17.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 17.13, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biocartis Group NV. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 17.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocartis Group NV's current EV-to-EBITDA is -3.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current EV-to-EBITDA of -3.71. The current EV-to-EBITDA is -3.71. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current EV-to-EBITDA is -3.71 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score
Get the complete analysis for LTS:0R72
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R72 has been successfully added to your 
